Pfizer, Inc. (NYSE: PFE) said on Friday that its Covid-19 Pill that is used in combination with a HIV drug, cuts risk of hospitalization or death by 89% n high risk adults who have been exposed to the virus. It is the second antiviral pill behind Merck’s to demonstrate strong effectiveness for treatment of Covid at the first sign of illness. This may be the game changer in the global pandemic issue that is Covid-19.
I think this medicine will change the way things are happening right now that will save millions and millions of lives, it has the potential to do it,” Bourla said in an interview on CNBC’s “Squawk Box.” He said the company has “the capacity right now of 500 million pills,” which he said translates to 50 million treatments. “The very high efficacy comes even to us as a surprise, exceeds our most visionary expectations we had for that.”
Pfizer reported six hospitalizations and zero deaths out of the 607 trial participants that received the pill in combination with the HIV drug within five days of symptom onset. This compares with 41 hospitalizations and 20 deaths out of the 612 people that received a placebo.
“These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” Pfizer CEO Albert Bourla said in a statement.
The post Pfizer said Covid Pill with HIV rug Cuts Risk of Hospitalization or Death by 89% first appeared on Financial Buzz .
For further details see:
Pfizer said Covid Pill with HIV rug Cuts Risk of Hospitalization or Death by 89%